FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300773022> ?p ?o ?g. }

• W4300773022 endingPage "42" @default.
• W4300773022 startingPage "32" @default.
• W4300773022 abstract "Advances in treatment have resulted in a significant increase in survival rates for patients cured of malignant diseases such as neuroblastoma (NBL) and extracranial germ cell tumor (GCT). NBL is one of the pediatric cancers during which potentially ototoxic cytostatic drugs (cisplatin and carboplatin) are used for treatment. Other cancers include germinal tumors, hepatoblastoma, sarcomas, and brain tumors. Often, this very aggressive treatment has a high risk of causing long-term side effects, including hearing loss. Hence, the present study aimed to evaluate the usefulness of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Brock, Chang, and International Society of Pediatric Oncology (SIOP) Boston scales in terms of detecting the high-frequency nature of hearing loss induced by ototoxic drugs and monitoring hearing status in children after completion of oncological treatment. Additionally, the frequency of hearing loss in children treated for NBL and extracranial GCT was assessed, and the principles of monitoring hearing in these patients were indicated.The study group consisted of 78 patients diagnosed with NBL (n = 47) and GCT (n = 31). There were 23 boys and 24 girls in the NBL group, aged 0-16 years, and 21 boys and 10 girls in the GCT group, aged 0-18 years. The control group consisted of 54 patients who had never received oncological treatment, were not taking potentially ototoxic drugs, and appeared socially efficient in the subjective audiological assessment. Audiometric examinations and DP-acoustic otoemission measurements were performed. Additionally, impedance audiometry tests were done to exclude a possible conductive component of the hearing loss.The analysis shows that ototoxicity-induced hearing loss was observed in 13.8-65.5% of children. 75.9% of patients showed hearing loss in the 16 kHz frequency range, and at least 56.8% of patients showed hearing loss in the frequency range above 12.5 kHz. Hearing impairment, relevant to speech understanding, was displayed by more than 40% of children treated for NBL and GCT.The confirmation of hearing loss in nearly 65% of cases in both patients indicates the necessity to monitor the long-term side effects of anticancer treatment. Acoustic otoemission measurements, the adoption of articulatory indices based on an audiogram, or the use of arbitrary ototoxicity assessment scales such as Brock, Chang, or SIOP Boston are fully justified techniques for studying ototoxicity induced by cytostatic drugs. However, they all require continuous improvement to increase their sensitivity and specificity, especially in the pediatric group." @default.
• W4300773022 created "2022-10-04" @default.
• W4300773022 creator A5058759496 @default.
• W4300773022 creator A5076083956 @default.
• W4300773022 creator A5080507831 @default.
• W4300773022 creator A5084544646 @default.
• W4300773022 date "2022-10-03" @default.
• W4300773022 modified "2023-10-15" @default.
• W4300773022 title "Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor" @default.
• W4300773022 doi "https://doi.org/10.1159/000526403" @default.
• W4300773022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36191558" @default.
• W4300773022 hasPublicationYear "2022" @default.
• W4300773022 type Work @default.
• W4300773022 citedByCount "0" @default.
• W4300773022 crossrefType "journal-article" @default.
• W4300773022 hasAuthorship W4300773022A5058759496 @default.
• W4300773022 hasAuthorship W4300773022A5076083956 @default.
• W4300773022 hasAuthorship W4300773022A5080507831 @default.
• W4300773022 hasAuthorship W4300773022A5084544646 @default.
• W4300773022 hasConcept C121608353 @default.
• W4300773022 hasConcept C126322002 @default.
• W4300773022 hasConcept C143998085 @default.
• W4300773022 hasConcept C2776694085 @default.
• W4300773022 hasConcept C2776715637 @default.
• W4300773022 hasConcept C2777793932 @default.
• W4300773022 hasConcept C2778239845 @default.
• W4300773022 hasConcept C2778534666 @default.
• W4300773022 hasConcept C2780493683 @default.
• W4300773022 hasConcept C2781451048 @default.
• W4300773022 hasConcept C2993561819 @default.
• W4300773022 hasConcept C54355233 @default.
• W4300773022 hasConcept C548259974 @default.
• W4300773022 hasConcept C71924100 @default.
• W4300773022 hasConcept C81885089 @default.
• W4300773022 hasConcept C86803240 @default.
• W4300773022 hasConceptScore W4300773022C121608353 @default.
• W4300773022 hasConceptScore W4300773022C126322002 @default.
• W4300773022 hasConceptScore W4300773022C143998085 @default.
• W4300773022 hasConceptScore W4300773022C2776694085 @default.
• W4300773022 hasConceptScore W4300773022C2776715637 @default.
• W4300773022 hasConceptScore W4300773022C2777793932 @default.
• W4300773022 hasConceptScore W4300773022C2778239845 @default.
• W4300773022 hasConceptScore W4300773022C2778534666 @default.
• W4300773022 hasConceptScore W4300773022C2780493683 @default.
• W4300773022 hasConceptScore W4300773022C2781451048 @default.
• W4300773022 hasConceptScore W4300773022C2993561819 @default.
• W4300773022 hasConceptScore W4300773022C54355233 @default.
• W4300773022 hasConceptScore W4300773022C548259974 @default.
• W4300773022 hasConceptScore W4300773022C71924100 @default.
• W4300773022 hasConceptScore W4300773022C81885089 @default.
• W4300773022 hasConceptScore W4300773022C86803240 @default.
• W4300773022 hasIssue "1" @default.
• W4300773022 hasLocation W43007730221 @default.
• W4300773022 hasLocation W43007730222 @default.
• W4300773022 hasOpenAccess W4300773022 @default.
• W4300773022 hasPrimaryLocation W43007730221 @default.
• W4300773022 hasRelatedWork W2000942526 @default.
• W4300773022 hasRelatedWork W2034320626 @default.
• W4300773022 hasRelatedWork W2073487097 @default.
• W4300773022 hasRelatedWork W2110043256 @default.
• W4300773022 hasRelatedWork W2175129957 @default.
• W4300773022 hasRelatedWork W2483354580 @default.
• W4300773022 hasRelatedWork W2947232861 @default.
• W4300773022 hasRelatedWork W4229488205 @default.
• W4300773022 hasRelatedWork W4287964903 @default.
• W4300773022 hasRelatedWork W4300773022 @default.
• W4300773022 hasVolume "28" @default.
• W4300773022 isParatext "false" @default.
• W4300773022 isRetracted "false" @default.
• W4300773022 workType "article" @default.